Highly potent payload is an exatecan derivative, known as DXd, with a short systemic half-life 1,3; Upon release, membrane-permeable payload causes DNA damage and cell death, resulting in …

2025年1月28日 · ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with unresectable or metastatic HER2-positive …

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to …

Indicated for unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer in adults who received prior anti-HER2-based regimen in the metastatic setting OR neoadjuvant …

ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the …

Trastuzumab deruxtecan is a HER2 directed antibody-drug conjugate (ADC). The humanized IgG1 monoclonal antibody (trastuzumab) is linked to DXd (topoisomerase I inhibitor) by a …

2024年12月3日 · In cycle 3, the apparent elimination half-life (t 1/2) of trastuzumab deruxtecan and released DXd was approximately 7 days. Moderate accumulation (approximately 35% in …

2019年5月20日 · Half-life. In a pharmacokinetic study, the median elimination half-life of trastuzumab deruxtecan was about 5.8 days. 6. Clearance. Trastuzumab deruxtecan is rapidly …

Enhertu™ trastuzumab deruxtecan is a HER2 targeted antibody drug conjugate (ADC). It contains a humanized anti-HER2 IgG1 monoclonal antibody (trastuzumab) attached to the cytotoxic …

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who …